...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Medical and Paediatric Oncology >Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
【24h】

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer

机译：Trastuzumab Deruxtecan：Her2阳性乳腺癌中的量子飞跃

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine. Most patients eventually develop resistance to systemic therapy. Trastuzumab deruxtecan, a novel HER2-targeted antibody drug conjugate, has shown to be promising in this subset. It is a HER2-targeted antibody drug conjugate structurally composed of humanized anti-HER2 monoclonal antibody, cleavable tetra-peptide-based liker, and a potent payload (topoisomerase 1 inhibitor: Exatecan). A phase 2 trial of heavily pretreated advanced HER2-positive breast cancer (median of six lines of prior therapy) showed an overall response of 61% and a median progression-free survival of 16 months. In December 2019, the Food and Drug Administration announced accelerated approval of trastuzumab deruxtecan for HER2-positive advanced breast cancer patients who were prior exposed to two or more lines of anti-HER2 therapy in a metastatic setting.
机译：Docetaxel，Trastuzumab和Pertuzumab，称为THP，是HER2阳性晚期乳腺癌的首选第一线治疗，第二线的首选药物是曲妥珠单抗。大多数患者最终造成了对系统性治疗的抵抗力。 Trastuzumab Deruxtecan是一种新的HER2靶向抗体药物缀合物，已经在这个亚空间中显示出具有很有希望的。它是由人源化抗HER2单克隆抗体，可切割的四肽的基于雌性和有效的有效载荷（Topoisomerase 1抑制剂：exatecan）构成的HER2靶向抗体药物缀合物。 2阶段对重症预处理的高级海拔Her2阳性乳腺癌（六条前疗法中位数）的试验表现出61％的总体反应和16个月的中位进展生存期。 2019年12月，食品和药物管理局宣布加速对HERASTUZIMAB Deruxtecan的批准，用于预先暴露于转移设置的两种或更多种抗HER2治疗线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号